Teijin Pharma Limited Report issue

For profit Phase 2
Founded: Tokyo Japan (2002)

Organization Overview

First Clinical Trial
2019
NCT04608838
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Teijin Pharma Limited

Active Ingredients

Drugs in Phase 2 Trials (1)

jtr-161 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 2)

Ischemia (Phase 2)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1